Point72 Asia (Singapore)’s Crinetics Pharmaceuticals CRNX Stock Holding History

Point72 Asia (Singapore)’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$537K	Buy	+12,889	New	+$412K	0.08%	158

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Point72 Asia (Singapore)'s CRNX Position: Q3 2025 in Review

Point72 Asia (Singapore) opened a new position in Crinetics Pharmaceuticals (CRNX) in Q3 2025: 12,889 shares worth $537K. The stake represents 0.08% of the portfolio and ranks #158 among its holdings.

225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

Point72 Asia (Singapore) held 12,889 shares of Crinetics Pharmaceuticals worth $537K as of Q3 2025.
Crinetics Pharmaceuticals was a new Point72 Asia (Singapore) position in Q3 2025.
Crinetics Pharmaceuticals made up 0.08% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #158 holding.
225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.